Clinical Trials - Patient Enrollment

AM-Pharma enrols first patients in Covid-19 phase III trial

AM-Pharma has recruited first patients with Covid-19 infection and sepsis-associated acute kidney injury (SA-AKI) in an exploratory cohort of its phase III REVIVAL pivotal trial.

FSD Pharma doses first patient in phase 2 Covid-19 trial of FSD201

FSD Pharma has dosed the first patients in its phase 2a clinical trial designed to assess FSD201 (ultramicronised palmitoylethanolamide or ultramicronised PEA) for the treatment of hospitalised patients with Covid-19.

Appili announces dosing of first patient in phase 3 Covid-19 trial

Appili Therapeutics announced that first patient has been dosed in the phase 3 PRESECO (preventing severe Covid disease) clinical trial to assess oral Avigan tablets (favipiravir) to treat Covid-19.

NeoImmuneTech doses first patient in Covid-19 trial

NeoImmuneTech has dosed the first patient in its phase 1 study designed to assess NT-I7 (efineptakin alfa) in adult patients with mild Covid-19.

Cerebral Therapeutics announces enrolment of first patient in phase 2b trial in epilepsy

Cerebral Therapeutics announced that the first patient has been enrolled in a Phase 2b study of intracerebroventricular drug delivery of the anti-seizure medication CT-010 in patients with medically refractory epilepsy.

NanOlogy enrols first patient in phase 2 trial of NanoPac for intratumoral treatment of prostate cancer

NanOlogy LLC, a clinical-stage oncology company advancing intratumoral therapy for solid tumors, has enrolled the first patient in a Phase 2 clinical trial of NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection for local prostate cancer.

Humanigen announces first patient dosed in phase 3 clinical study of lenzilumab in Covid-19

Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, today announced that MedStar Washington Hospital Center in Washington, D.C. treated its first Covid-19 patient with lenzilumab.

ImmunityBio, NantKwest dose first patient in novel Covid-19 vaccine candidate trial

ImmunityBio and NantKwest have dosed the first patient in phase I clinical study of a novel Covid-19 vaccine candidate called hAd5-Covid-19.

Rigel enrols first patients in phase 2 Covid-19 trial of fostamatinib

Rigel Pharmaceuticals has recruited the first patients in a phase 2 study designed to assess the safety of fostamatinib for the treatment of hospitalised Covid-19 patients.